newsfilter
← Latest News
GlobeNewswire·

Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones

  • Can-Fite BioPharma Ltd. is participating in BIO-Europe 2026 in Cologne, Germany, from November 9–11, with digital sessions scheduled for November 17–18.
  • Dr. Sari Fishman, Vice President of Business Development, will represent the company to pursue licensing, co-development, commercialization partnerships, & other strategic transactions.
  • Namodenoson for pancreatic cancer showed positive Phase IIa results at ESMO 2026, featuring a favorable safety profile & encouraging exploratory survival findings.
  • Namodenoson for liver cancer is in a pivotal Phase III study for advanced hepatocellular carcinoma, with longer-than-anticipated blinded overall survival observed & an interim analysis planned.
  • Piclidenoson for psoriasis is in a pivotal Phase III program that reached its prespecified interim analysis stage, with results expected in the first quarter of 2027.
  • Namodenoson for MASH is in an ongoing Phase IIb clinical development program targeting a significant global market.
  • Piclidenoson for Lowe Syndrome is in a rare disease program supported by a collaboration with Fondazione Telethon & strengthened by a recent Eurasian patent allowance.
  • The company has established multiple regional licensing agreements generating approximately $20 million in upfront & milestone payments to date.
  • Can-Fite's drug candidates have demonstrated an excellent safety profile across over 1,600 patients in clinical studies.
  • Namodenoson holds Orphan Drug Designation in the U.S. & Europe, plus Fast Track Designation in the U.S. for second-line HCC treatment.
  • Forward-looking statements regarding future clinical progress, regulatory approvals, & partnership outcomes are included with associated risk disclosures.
Company
Can-Fite BioPharma Ltd.
Keywords
NYSE:CANF, Can-Fite BioPharma Ltd., anti-Cancer, Biotechnology, ClinicalStudy